Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2025-12-24 @ 4:01 PM
NCT ID:
NCT04324866
Eligibility Criteria:
Group 1
Inclusion Criteria:
* Aged 18 to 75 years old
* Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis confirmed by the Investigator
* Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate, ciclsoporin, acitretin) for the past 3 months
* Is willing and able to sign informed consent to participate
Exclusion Criteria:
* Patients unwilling to undergo noasopharyngeal swab
* Inability to give informed consent
Group 2
Inclusion Criteria:
* Aged 18 to 75 years old
* Partner of a patient with psoriasis enrolled in the study
* Is willing and able to sign informed consent to participate
Exclusion Criteria:
* Personal history of psoriasis
* Ongoing immunosuppressive therapy
* Patients unwilling to undergo noasopharyngeal swab
* Inability to give informed consent
Group 3
* Aged 18 to 75 years old
* Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis confirmed by the Investigator
* Continuous therapy with dupilumab for the past 3 months
* Is willing and able to sign informed consent to participate
Exclusion Criteria:
* Patients unwilling to undergo noasopharyngeal swab
* Inability to give informed consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04324866
Study Brief:
Protocol Section:
NCT04324866